Psychedelics

Psychedelics for Mental Health

Are psychedelics just a fad in mental healthcare?

We don't think so given that the FDA just approved, Esketamine, as the first new anti-depressant in the last 25 years.

Psychedelic medicines, a broad category of substances that can cause changed perspective and sensory impressions, is said to reset the brain and allow users to better process memories, feelings and past trauma.

Studies have shown that psychedelic chemicals, like psilocybin, can decrease excessive drinking by 83 percent on average among heavy drinkers and they can be an effective treatment for mental health conditions such as depression. Now psychedelic companies are investing in tech to uncover new compounds with AI, develop digital biomarkers to tailor doses and broaden access through telehealth services.

However, participating in existing psychotherapy clinical trials is resource-intensive and out of reach for many who are socioeconomically disadvantaged. This inequity is particularly bothersome because Western psychedelic medicine is inexorably rooted to Indigenous and queer healing traditions.

With the global market for psychedelics expected to reach $10 billion by 2027 ,

equitable access to psychotherapies is the least the health tech community should ensure in its future growth.

________________________________________________________________      

In the News

________________________________________________________________

How AI could unlock the medical potential of psychedelics

Pharmaceutical Technology

VA Studying Psychedelics As Mental Health Treatment for Veterans

Forbes

Digital Therapeutics And The Future of Psychedelic Medicine

Markets Insider

Digital health and therapeutics will play a crucial role in the future of medicine. Some companies are positioning themselves as leaders in the psychedelic medicine space. Entheo's SoundSelf could be a digital therapeutic that can render an altered state of consciousness. MindCure has completed the first stage of manufacturing pharmaceutical-grade ibogaine for clinical research. iSTRYM technology is an innovative software application built to optimize the healing journey for both patients and clinicians.

Whitewashing psychedelics: racial equity in the emerging field of psychedelic-assisted mental health research and treatment

Taylor & Francis

Digital therapeutics and telehealth set to transform psychedelic therapy

Psych Global 

The Therapeutic Potential of Psychedelic Medicine for Aging Populations

Generations